Physician profile
Simon C Oh
NPI 1649236191
$112,380.86
in general payments reported to CMS, 2019-2025
67 companies · $16K in 2025
The $16K reported for 2025 was more than what 92% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $5,820 · 2021: $21K · 2022: $28K · 2023: $13K · 2024: $7,389 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Consulting Fee: $4,800 · Travel and Lodging: $2,033 · Education: $83.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16,502.78 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,104.00 |
| Consulting Fee | $4,800.00 |
| Travel and Lodging | $2,033.48 |
| Education | $83.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $35,355.01 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $15,800.77 | 2019-2025 | Ultomiris |
| Teva Pharmaceuticals USA, INC. | $11,559.77 | 2019-2025 | Ajovy, Austedo Xr, Austedo |
| Pfizer INC. | $7,244.84 | 2021-2025 | |
| Argenx US, INC. | $7,027.36 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Grifols USA, LLC | $6,353.39 | 2019-2024 | Gamunex-C |
| Livanova USA, INC. | $4,656.00 | 2019-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Allergan, INC. | $2,998.93 | 2019-2022 | |
| Sk Life Science, INC. | $2,366.80 | 2021-2025 | Xcopri |
| Ucb, INC. | $2,140.12 | 2019-2025 | Briviact, Nayzilam, Fintepla |
| Amgen INC. | $1,396.35 | 2019-2024 | Aimovig, Uplizna |
| Lundbeck LLC | $1,212.84 | 2019-2025 | Vyepti |
| Celgene Corporation | $1,206.03 | 2022-2024 | Zeposia |
| Abbott Laboratories | $1,088.72 | 2020-2025 | Infinity |
| Eisai INC. | $885.43 | 2019-2023 |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simon Oh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.